NRA Holly Hill Dialysis Center is a medicare approved dialysis facility center in Holly Hill, South Carolina and it has 16 dialysis stations. It is located in Orangeburg county at 8532 Old State Road, Holly Hill, SC, 29059. You can reach out to the office of NRA Holly Hill Dialysis Center at (803) 496-2800. This dialysis clinic is managed and/or owned by Fresenius Medical Care. NRA Holly Hill Dialysis Center has the following ownership type - Profit. It was first certified by medicare in October, 2003. The medicare id for this facility is 422593 and it accepts patients under medicare ESRD program.
| Name | NRA Holly Hill Dialysis Center |
|---|---|
| Location | 8532 Old State Road, Holly Hill, South Carolina |
| No. of Dialysis Stations | 16 |
| Medicare ID | 422593 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 8532 Old State Road, Holly Hill, South Carolina, 29059 | |
| (803) 496-2800 | |
| Not Available |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
| NPI Number | 1124061809 |
| Organization Name | Holly Hill Dialysis Clinic |
| Doing Business As | Nra Holly Hill South Carolina Llc |
| Address | 8532 Old State Road Holly Hill, South Carolina, 29059 |
| Phone Number | (803) 496-2800 |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 27 |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 66 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 571 |
| Percentage of adult patients getting regular hemodialysis at the center | |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at NRA Holly Hill Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 69 |
| Hypercalcemia patient months | 590 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | |
| Patients with Serumphosphor | 73 |
| Patients with Serumphosphor less than 3.5 mg/dL | |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | |
| Patients with Serumphosphor greater than 7 mg/dL |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 59 |
| Patient months included in arterial venous fistula and catheter summaries | 425 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Genmab A/S has announced that its partner Roche has filed an Investigational New Drug application (IND) with the US Food and Drug Administration for a Genmab antibody developed under the companies' collaboration.
HyGreen™, developed by Xhale Innovations, Inc., has been selected as a winner in the 2010 Medical Design Excellence Awards competition, one of the most prestigious awards in the medical device industry. The announcement comes on the heels of winning the 2009 Popular Science Best of What's New Award, and is the latest success for this market-defining product.
Former patients of former doctor, Graeme Reeves are being urged to come forward and attend a public meeting today to discuss a potential class action.
Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.
› Verified 6 days ago